Table 2

Secondary outcomes (fasting) from study

Median (interquartile range)

P-values

0 weeks

6 weeks

12 weeks

0-6 weeks

6-12 weeks

Total cholesterol, mg/dL

165 (146, 181)

166 (130, 178)

173 (146, 184)

0.18

0.0002

High density lipoprotein, mg/dL

45 (39, 57)

48 (3, -57)

47 (43, 60)

0.95

0.02

Low density lipoprotein, mg/dL

91 (79, 120)

83 (70, 102)

89 (81, 126)

0.15

0.003

Triglycerides, mg/dL

85 (64, 98)

75 (52, 116)

81(71, 98)

0.33

0.95

C-reactive protein, mg/L

2.80 (1.3, 4.6)

2.98 (1.7, 3.4)

1.91(1.1, 6.3)

0.47

0.96

Fasting insulin, μIU/mL

10.44 (6.89, 22.7)

9.37 (4.27, 10.26)

10.48 (6.87, 17.01)

0.09

0.45

Glucose, mg/dL

92 (77, 95)

88 (76, 97)

86 (80, 97)

0.64

0.72

C-peptide, ng/mL

3.81 (2.21, 4.35)

3.05 (2.32, 4.20)

3.30 (2.15, 4.37)

0.49

0.35

Interleukin-6, pg/mL

2.90 (2.15, 3.92)

3.06 (2.13, 3.84)

3.12 (2.64, 4.03)

0.81

0.62

Mercer et al. Arthritis Research & Therapy 2012 14:R135   doi:10.1186/ar3868